About: Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.99 (-3.15%)
CMPX NASDAQ Compass Therapeutics Inc.
Compass Therapeutics Inc. share price
CMPX price activity
Último preço
$ 0,990
Variação (24h)
-0,03 USD (-3,15%)
Volume
3.47M
Volume (média 4 sem.)
-
Abertura
$ 1,01
Variação do dia
$ 0,96 - $ 1,01
Fechamento anterior
$ 1,02
Último negócio
08 Oct, 6:37 pm GMT+0
Atrasado
08 Oct, 6:37 pm GMT+0
CMPX price performance
Atrasado
08 Oct, 6:37 pm GMT+0
quote.marketSignals